Merck(US:MRK) GLP1减重宝典·2026-02-09 11:16Core Viewpoint - The article discusses the competitive landscape of GLP-1 weight loss drugs, highlighting the strategic differentiation among multinational corporations (MNCs) and the emergence of small molecule GLP-1 as a preferred choice for latecomers in the market [4][6][7]. Group 1: MNC Strategies in GLP-1 Market - Major players like Eli Lilly and Novo Nordisk have adopted a "full-dimensional coverage" strategy, developing a range of formulations from injectable to oral, and targeting single to multi-target agonists to create a systemic competitive advantage [6]. - Companies entering the market later, such as Roche and AstraZeneca, are focusing on differentiated approaches, with Roche acquiring assets to enhance mechanism diversity and AstraZeneca targeting small molecule GLP-1 for its oral potential [6][7]. Group 2: Small Molecule GLP-1 as a Strategic Choice - The trend towards small molecule GLP-1 is driven by its advantages in manufacturing costs, administration convenience, and potential for long-term use, contrasting with injectable peptides [7]. - Merck's initiation of the MK-4082 phase I clinical trial represents an extension of its traditional strengths in metabolic diseases, while Pfizer has made significant acquisitions to bolster its presence in the weight loss sector [7]. Group 3: Chinese Companies in the GLP-1 Space - Chinese firm Heng Rui Pharma has initiated three phase III clinical trials for its GLP-1/GIP project, positioning itself ahead in global development timelines [8]. - Other Chinese companies, such as Cheng Yi Bio and Hansoh Pharma, are also advancing in the small molecule GLP-1 arena, enhancing the international presence of Chinese assets in this competitive field [8].